Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma

Sorafenib has been demonstrated to be a beneficial treatment for advanced hepatocellular carcinoma (HCC). Emerging evidence indicates that caspase-1 activation plays a crucial role in HCC progression. However, the relationship between caspase-1 and sorafenib has rarely been reported. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Zhou, Yuan, Liu, Yang, Dai, Bo, Zhang, Yu-Hen, Zhang, Peng-Fei, Shi, Xiao-Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301813/
https://www.ncbi.nlm.nih.gov/pubmed/30277836
http://dx.doi.org/10.1080/15384047.2018.1480280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301813/
https://www.ncbi.nlm.nih.gov/pubmed/30277836
http://dx.doi.org/10.1080/15384047.2018.1480280

Ejemplares similares